Marginal Zone Lymphoma
📧 Sign up to get email alerts when something new happens for Marginal Zone Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-06-11Clinical Trial Update: Clinical Study of OR for Second-line Treatment of Refractory MZL [Phase 4]
Phase 4 trial evaluating the OR Regimen for relapsed/refractory marginal zone lymphoma is currently recruiting. This study investigates a se…
-
CLINICAL_TRIALS trial_result · 2024-06-05Clinical Trial Update: IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma [Phase 2]
Phase 2 clinical trial update on IBI376 in relapsed or refractory follicular lymphoma and marginal zone lymphoma. The study status is comple…
-
CLINICAL_TRIALS research · 2024-05-23Clinical Trial Update: BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.
This clinical trial update discusses the implications of BCL6 rearrangements across non-Hodgkin lymphomas, including follicular lymphoma, ma…
-
CLINICAL_TRIALS withdrawal · 2024-04-25Clinical Trial Update: CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL [Phase 1]
A Phase 1 trial investigating CpG-STAT3 siRNA CAS3/SS3 with localized radiation for relapsed/refractory B-cell non-Hodgkin lymphomas has bee…
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL) [Phase 2]
Phase 2 trial update for ICP-022 in relapsed/refractory marginal zone lymphoma has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-02-08FDA Approved: VIVIMUSTA — Supplemental Application (Azurity Pharmaceuticals, Inc.)
The FDA approved a supplemental application for VIVIMUSTA (bendamustine hydrochloride) filed by Azurity Pharmaceuticals, Inc., to update/exp…
-
CLINICAL_TRIALS trial_result · 2024-02-01Clinical Trial Update: Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) [Phase 2]
The phase 2 TIDAL trial of Zandelisib (ME-401) in follicular lymphoma, non-Hodgkin lymphoma, and marginal zone lymphoma was terminated, with…
-
CLINICAL_TRIALS trial_result · 2023-12-13Clinical Trial Update: Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) [Phase 3]
Phase 3 trial COASTAL evaluating Zandelisib in combination with Rituximab in indolent non-Hodgkin lymphoma was terminated; results were post…
-
CLINICAL_TRIALS trial_result · 2023-11-09Clinical Trial Update: Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma [Phase 2]
Phase 2 trial evaluating ublituximab followed by response-driven addition of umbralisib for treatment-naive follicular lymphoma or marginal …
-
CLINICAL_TRIALS trial_result · 2023-06-23Clinical Trial Update: Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial assessing efficacy and safety of umbralisib in non-follicular indolent non-Hodgkin lymphoma has completed with results posted …
-
CLINICAL_TRIALS trial_result · 2023-06-09Clinical Trial Update: High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant [Phase 2]
Phase 2 clinical trial evaluating high-dose cyclophosphamide, tacrolimus, and mycophenolate mofetil to prevent graft-versus-host disease in …
-
FDA approval · 2023-03-24FDA Approved: LENALIDOMIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for lenalidomide submitted by Sun Pharmaceutical Industries, Inc.
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas [Phase 2]
Phase 2 trial of pembrolizumab alone or with idelalisib or ibrutinib in relapsed/refractory chronic lymphocytic leukemia or various low-grad…
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Teva Pharmaceuticals, Inc.)
FDA approved a generic lenalidomide product for Teva under ANDA201452, expanding access to lenalidomide formulations.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (EXELAN PHARMACEUTICALS INC.)
FDA approves a generic lenalidomide product from Exelan Pharmaceuticals under an original application. The drug is indicated for several hem…
-
EMA withdrawal · 2023-02-10EMA Application withdrawn: Aliqopa (copanlisib dihydrochloride) — Bayer AG
The EMA has withdrawn the application for Aliqopa (copanlisib dihydrochloride) by Bayer AG for its use in lymphoma subtypes including margin…
-
FDA approval · 2023-02-08FDA Approved: LENALIDOMIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approves Sun Pharmaceutical Industries' Lenalidomide Original Application, granting a generic lenalidomide product for multiple myeloma …
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas [Phase 2]
Phase 2 clinical trial evaluating the atezolizumab-venetoclax-obinutuzumab combination in relapse/refractory lymphomas has completed enrollm…
-
CLINICAL_TRIALS trial_result · 2022-12-30Clinical Trial Update: Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases [Phase 2]
A Phase 2 pembrolizumab trial in untreated B-cell non-Hodgkin lymphoproliferative diseases has been terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2022-11-21Clinical Trial Update: Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update on ublituximab for relapsed or refractory B-cell non-Hodgkin lymphoma completed phases 1 and 2.
-
CLINICAL_TRIALS trial_result · 2022-09-19Clinical Trial Update: Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma [Phase 2]
Phase 2 trial evaluating acalabrutinib in combination with the R-ICE chemotherapy regimen for relapsed or refractory lymphoma; the study was…
-
CLINICAL_TRIALS trial_result · 2022-07-21Clinical Trial Update: Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma [Phase 2, Phase 3]
Phase 2/3 trial assessing ublituximab + umbralisib with or without bendamustine, and umbralisib alone, in previously treated non-Hodgkin lym…
-
CLINICAL_TRIALS withdrawal · 2022-07-18Clinical Trial Update: To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) [Phase 3]
A Phase 3 clinical trial evaluating parsaclisib with rituximab or obinutuzumab in relapsed/refractory follicular lymphoma and marginal zone …
-
FDA approval · 2022-07-06FDA Approved: ZYDELIG — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for ZYDELIG (idelalisib) submitted by Gilead Sciences, Inc. The specific changes to the product'…
-
FDA label_change · 2022-06-30FDA Approved: LENALIDOMIDE — Supplemental Application (Dr. Reddy's Laboratories Inc.)
FDA approved a supplemental application for lenalidomide submitted by Dr. Reddy's Laboratories Inc., resulting in updated labeling for the d…